BBIO
BridgeBio Pharma, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-13/100
Last price
66.99
▲ 0.85 (1.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
66.00
Prev close
66.14
Day high
68.12
Day low
65.71
Volume
3.71M
Market cap
$13.09B
P/E (TTM)
—
52W range
52.75 – 93.42
Day trading desk
Gap from prior close
-0.21%
Prior close 66.14
VWAP
67.03
-0.05% from price
Relative volume
2.49×
Unusually busy
Session range
10.73%
63.00 – 69.76
Position in range
59%
Mid range
ATR (14D)
2.44
3.64% of price
Prior day high
68.08
PDH
Prior day low
65.46
PDL
Bid / ask spread
—
Quote not published
Session volume
6.82M
Avg 2.73M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.50%
-0.4%
1M
-10.53%
-11.7%
3M
-14.52%
-19.0%
6M
-6.91%
-25.1%
YTD
-12.46%
-26.7%
1Y
+26.67%
+10.3%
3Y
+153.92%
+71.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BBIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-159.97K
Net selling
Buy transactions
20
489.13K shares
Sell transactions
15
649.10K shares
Net transactions
+35
Buys less sells
Sell : buy shares
1.3 : 1
Mixed
Insider-held shares
7.65M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 17, 26 | KUMAR NEIL Chief Executive Officer |
SELL | 10.00K | $690.85K | Indirect |
| Aug 19, 26 | KUMAR NEIL Chief Executive Officer |
SELL | 44.98K | $3.73M | |
| Aug 14, 26 | KUMAR NEIL Chief Executive Officer |
— | 71.22K | — | Direct |
| Jul 30, 26 | APULI MARICEL Officer |
SELL | 2.00K | $160.12K | Direct |
| Jul 9, 26 | COOK JENNIFER E Director |
SELL | 148.59K | $13.16M | Direct |
| Jul 9, 26 | ELLIS ANDREA Director |
SELL | 17.17K | $1.44M | Direct |
| Jul 9, 26 | COOK JENNIFER E Director |
CONVERSION | 148.59K | $3.71M | Direct |
| Jul 9, 26 | ELLIS ANDREA Director |
CONVERSION | 17.17K | $287.55K | Direct |
| Jun 24, 26 | COOK JENNIFER E Director |
SELL | 39.36K | $2.75M | Direct |
| Jun 24, 26 | COOK JENNIFER E Director |
CONVERSION | 37.17K | $456.55K | Direct |
| Jun 23, 26 | VALANTINE HANNAH A. Director |
SELL | 5.00K | $341.52K | Direct |
| Jun 22, 26 | HOMCY CHARLES J Director |
STOCK | 3.99K | $0 | Direct |
| Jun 22, 26 | MCCORMICK FRANK P. PH.D. Director |
STOCK | 3.99K | $0 | Direct |
| Jun 22, 26 | DANIELS RONALD J Director |
STOCK | 3.99K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
APULI MARICEL |
Officer | 127.40K | Sale |
HOMCY CHARLES J |
Director | 919.88K | Stock Award(Grant) |
KKR GENETIC DISORDER L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
KUMAR NEIL |
Chief Executive Officer | — | Sale |
MCCORMICK FRANK P. PH.D. |
Director | 767.24K | Stock Award(Grant) |
MOMTAZEE JAMES C |
Director | 99.07K | Stock Award(Grant) |
SATVAT ALI J |
Director | 169.98K | Stock Award(Grant) |
STEPHENSON BRIAN C |
Chief Financial Officer | 102.46K | Sale |
TRIMARCHI THOMAS |
President | 359.19K | Sale |
VIKING GLOBAL INVESTORS LP |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$13.09B
Enterprise value$15.75B
Revenue (TTM)$713.07M
Gross profit$673.41M
EBITDA$-472.75M
Net income$-691.87M
EPS (TTM)$-3.60
Free cash flow$-320.26M
Total cash$720.16M
Total debt$3.37B
Book value / share$-12.88
Shares outstanding195.49M
Float167.19M
Short % of float12.31%
Dividend yield0.00%
Beta (5Y)0.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E2,437.57
PEG ratio—
Price / sales—
Price / book—
EV / revenue22.09
EV / EBITDA-33.32
Gross margin94.44%
Operating margin-43.94%
Profit margin-97.03%
Return on equity—
Return on assets-26.00%
Debt / equity—
Current ratio1.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $502.08M | $221.90M | $9.30M | $77.65M | +126.3% |
| Operating revenue | $502.08M | $221.90M | $9.30M | $77.65M | +126.3% |
| Cost of revenue | $20.96M | $3.88M | $2.45M | $3.43M | +440.5% |
| Gross profit | $481.11M | $218.02M | $6.86M | $74.21M | +120.7% |
| Research & development | $451.95M | $506.46M | $455.71M | $399.46M | -10.8% |
| Selling, general & admin | $531.23M | $288.93M | $150.59M | $143.19M | +83.9% |
| Total operating expense | $983.18M | $795.39M | $606.30M | $542.65M | +23.6% |
| Operating income | -$502.06M | -$577.37M | -$599.44M | -$468.44M | +13.0% |
| Net interest income | -$158.39M | -$82.04M | -$63.25M | -$72.90M | -93.1% |
| Pre-tax income | -$732.50M | -$542.19M | -$653.25M | -$484.65M | -35.1% |
| Tax provision | $435.00K | $1.15M | $0 | $0 | -62.3% |
| Net income | -$724.93M | -$535.76M | -$643.20M | -$481.18M | -35.3% |
| Net income to common | -$724.93M | -$535.76M | -$643.20M | -$481.18M | -35.3% |
| Basic EPS | -3.78 | -2.88 | -3.95 | -3.26 | -31.3% |
| Diluted EPS | -3.78 | -2.88 | -3.95 | -3.26 | -31.3% |
| EBIT | -$554.26M | -$442.90M | -$571.96M | -$404.21M | -25.1% |
| EBITDA | -$548.83M | -$436.83M | -$565.47M | -$397.44M | -25.6% |
| Basic shares | 191.53M | 186.08M | 162.79M | 147.47M | +2.9% |
| Diluted shares | 191.53M | 186.08M | 162.79M | 147.47M | +2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $570.12M | $681.10M | $375.94M | $376.69M | -16.3% |
| Cash & short-term investments | $587.48M | $681.10M | $434.88M | $471.92M | -13.7% |
| Accounts receivable | $139.44M | $4.72M | $1.75M | — | +2,853.1% |
| Inventory | $26.75M | $0 | — | — | — |
| Total current assets | $797.75M | $720.69M | $477.59M | $548.85M | +10.7% |
| Property, plant & equipment | $13.52M | $12.78M | $19.84M | $25.25M | +5.8% |
| Goodwill & intangibles | $28.08M | $23.93M | $26.32M | $28.71M | +17.3% |
| Total assets | $936.02M | $919.34M | $546.38M | $623.04M | +1.8% |
| Total current liabilities | $287.97M | $154.40M | $143.84M | $121.43M | +86.5% |
| Long-term debt | $1.85B | $1.72B | $1.73B | $1.71B | +7.6% |
| Total debt | $1.86B | $1.73B | $1.74B | $1.72B | +7.6% |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | +26.7% |
| Retained earnings | -$3.82B | -$3.10B | -$2.56B | -$1.92B | -23.4% |
| Shareholder equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -42.1% |
| Working capital | $509.78M | $566.29M | $333.75M | $427.43M | -10.0% |
| Net tangible assets | -$2.11B | -$1.49B | -$1.38B | -$1.28B | -41.8% |
| Shares issued | 202.37M | 196.24M | 181.27M | 156.82M | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$732.94M | -$543.35M | -$653.25M | -$484.65M | -34.9% |
| Depreciation & amortisation | $5.43M | $6.08M | $6.49M | $6.77M | -10.6% |
| Stock-based compensation | $133.02M | $95.80M | $108.71M | $91.56M | +38.9% |
| Change in working capital | -$51.06M | $32.04M | $5.06M | $28.08M | -259.4% |
| Operating cash flow | -$445.91M | -$520.73M | -$527.72M | -$419.49M | +14.4% |
| Capital expenditure | -$9.59M | -$8.91M | -$1.31M | -$6.32M | -7.7% |
| Investing cash flow | -$24.49M | $60.78M | $54.03M | $453.15M | -140.3% |
| Share buybacks | -$62.50M | -$7.53M | -$6.88M | -$1.56M | -730.5% |
| Financing cash flow | $359.29M | $748.46M | $451.54M | -$13.13M | -52.0% |
| Free cash flow | -$455.50M | -$529.63M | -$529.03M | -$425.81M | +14.0% |
| End cash position | $572.14M | $683.24M | $394.73M | $416.88M | -16.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $243.68M | $194.51M | $154.18M | $120.70M | $110.56M | +25.3% |
| Operating revenue | $243.68M | $194.51M | $154.18M | $120.70M | $110.56M | +25.3% |
| Cost of revenue | $15.05M | $9.94M | $8.11M | $6.56M | $3.65M | +51.4% |
| Gross profit | $228.63M | $184.58M | $146.07M | $114.14M | $106.91M | +23.9% |
| Research & development | $149.45M | $126.64M | $116.42M | $112.87M | $111.23M | +18.0% |
| Selling, general & admin | $186.26M | $163.90M | $158.09M | $137.62M | $129.15M | +13.6% |
| Total operating expense | $335.71M | $290.53M | $274.50M | $250.50M | $240.38M | +15.5% |
| Operating income | -$107.08M | -$105.96M | -$128.43M | -$136.36M | -$133.47M | -1.1% |
| Net interest income | -$47.96M | -$46.57M | -$45.98M | -$41.91M | -$33.74M | -3.0% |
| Pre-tax income | -$155.89M | -$166.56M | -$194.75M | -$186.48M | -$181.66M | +6.4% |
| Tax provision | $0 | — | -$120.00K | -$1.54M | $2.10M | — |
| Net income | -$152.22M | -$164.04M | -$192.86M | -$182.74M | -$181.90M | +7.2% |
| Net income to common | -$152.22M | -$164.04M | -$192.86M | -$182.74M | -$181.90M | +7.2% |
| Basic EPS | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 | +7.1% |
| Diluted EPS | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 | +7.1% |
| EBIT | -$101.27M | -$113.74M | -$144.44M | -$138.33M | -$144.02M | +11.0% |
| EBITDA | -$100.22M | -$112.55M | -$143.01M | -$136.94M | -$142.70M | +11.0% |
| Basic shares | 195.79M | 194.79M | 193.55M | 191.85M | 190.52M | +0.5% |
| Diluted shares | 195.79M | 194.79M | 193.55M | 191.85M | 190.52M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $677.91M | $879.89M | $570.12M | $642.95M | $748.95M | -23.0% |
| Cash & short-term investments | $720.16M | $940.19M | $587.48M | $645.94M | $756.89M | -23.4% |
| Accounts receivable | $254.48M | $205.23M | $139.44M | $116.52M | $76.87M | +24.0% |
| Inventory | $52.84M | $32.98M | $26.75M | $24.53M | $18.28M | +60.2% |
| Total current assets | $1.09B | $1.24B | $797.75M | $839.38M | $912.28M | -11.9% |
| Property, plant & equipment | $22.30M | $22.17M | $13.52M | $12.38M | $12.29M | +0.6% |
| Goodwill & intangibles | $26.64M | $27.36M | $28.08M | $28.80M | $29.51M | -2.6% |
| Total assets | $1.22B | $1.37B | $936.02M | $998.25M | $1.08B | -11.2% |
| Total current liabilities | $890.65M | $816.37M | $287.97M | $216.60M | $175.85M | +9.1% |
| Current debt | $547.96M | $547.48M | — | — | — | +0.1% |
| Long-term debt | $1.93B | $1.93B | $1.85B | $1.85B | $1.85B | +0.1% |
| Total debt | $2.49B | $2.49B | $1.86B | $1.86B | $1.86B | +0.1% |
| Total liabilities | $3.72B | $3.64B | $3.01B | $2.92B | $2.86B | +2.3% |
| Retained earnings | -$4.14B | -$3.99B | -$3.82B | -$3.63B | -$3.45B | -3.8% |
| Shareholder equity | -$2.52B | -$2.28B | -$2.09B | -$1.93B | -$1.79B | -10.4% |
| Working capital | $202.49M | $424.93M | $509.78M | $622.78M | $736.42M | -52.3% |
| Net tangible assets | -$2.54B | -$2.31B | -$2.11B | -$1.96B | -$1.82B | -10.2% |
| Shares issued | 195.28M | 204.39M | 202.37M | 200.23M | 198.76M | -4.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$155.89M | -$166.56M | -$194.63M | -$184.94M | -$183.76M | +6.4% |
| Depreciation & amortisation | $1.05M | $1.19M | $1.44M | $1.40M | $1.32M | -11.2% |
| Stock-based compensation | $44.07M | $33.24M | $34.64M | $35.26M | $37.24M | +32.6% |
| Change in working capital | -$9.29M | -$124.74M | $49.61M | -$3.93M | $19.42M | +92.6% |
| Operating cash flow | -$71.10M | -$197.28M | -$56.42M | -$109.57M | -$80.68M | +64.0% |
| Capital expenditure | -$443.00K | -$69.00K | -$33.00K | -$2.87M | -$5.09M | -542.0% |
| Investing cash flow | $17.89M | -$42.73M | -$14.35M | $4.46M | -$13.00M | +141.9% |
| Share buybacks | -$131.77M | -$86.57M | -$7.43M | -$3.02M | -$2.00M | -52.2% |
| Financing cash flow | -$148.77M | $549.89M | -$2.18M | -$894.00K | $302.04M | -127.1% |
| Free cash flow | -$71.54M | -$197.35M | -$56.45M | -$112.44M | -$85.78M | +63.7% |
| End cash position | $680.04M | $882.02M | $572.14M | $645.10M | $751.10M | -22.9% |
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
2.86
Positioning, not flow
Max pain
67.50
+0.8% from spot
ATM implied vol
73.5%
Nearest strike to spot
Skew (10% OTM)
-4.3%
Calls bid over puts
Call volume
586
Contracts, this expiry
Put volume
80
Contracts, this expiry
Heaviest call OI
75.00
621 contracts
Heaviest put OI
65.00
4.75K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.58 | -0.78 | -33.9% |
| Mar 2026 | -0.62 | -0.84 | -36.2% |
| Dec 2025 | -0.62 | -0.94 | -50.6% |
| Sep 2025 | -0.78 | -0.72 | +7.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.63 | 7 | $270.21M | +123.9% |
| Next quarter | -0.44 | 7 | $316.70M | +105.4% |
| Current year | -2.58 | 8 | $1.03B | +104.5% |
| Next year | 0.03 | 7 | $1.70B | +65.3% |
Analyst targets & ownership
Mean target$109.05
High target$156.00
Low target$80.00
Implied upside62.78%
Analyst count21
ConsensusSTRONG BUY
Strong buy / Buy5 / 14
Hold3
Sell / Strong sell0 / 0
Held by insiders3.91%
Held by institutions99.57%
Institutions holding646
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
66.32
+1.01% from price
SMA 20
68.15
-1.75% from price
SMA 50
75.62
-11.45% from price
SMA 100
74.23
-9.75% from price
SMA 200
73.50
-8.89% from price
EMA 12
67.23
-0.36% from price
EMA 26
69.84
-4.07% from price
EMA 50
72.56
-7.67% from price
RSI (14)
38.5
Neutral
MACD (12,26,9)
-2.60
Hist 0.37
ATR (14)
2.44
3.65% of price
Realised vol 30D
31.4%
Annualised
Bollinger upper
73.83
20, 2σ
Bollinger lower
62.47
20, 2σ
50 / 200 cross
Golden
75.62 vs 73.50
Trend bias
Below 200
-8.89%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.08
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
31.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.3%
Peak to trough
Max drawdown 5Y
-90.2%
Peak to trough
ATR 14
2.44
3.65% of price
Beta (reported)
0.97
5Y monthly, from filing
Short interest
Shares short
21.55M
Prior 23.32M
Change vs prior
-7.6%
Shorts covering
% of float
12.31%
Elevated
% of shares out
11.02%
Against total outstanding
Days to cover
10.6
Crowded exit
Float
167.19M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 1, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 12, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 12, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 11, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 11, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 11, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 11, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-17
Corporate Changes & Voting Matters
8-K · 2026-08-10
Offering Registrations
S-3ASR · 2026-07-24
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-05-27
Headlines
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
GlobeNewswire · 8h ago
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
GlobeNewswire · 8h ago
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
PR Newswire · 11h ago
Sector Update: Healthcare Stocks Rise Premarket Tuesday
MT Newswires · 15h ago
BridgeBio Pharma's New Drug Application for Genetic Short Stature Condition Accepted by US FDA
MT Newswires · 16h ago
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
GlobeNewswire · 16h ago
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
GlobeNewswire · 1d ago
BridgeBio Says Interim Analysis of BBP-418 Showed Individuals Reaching Normal Levels on Limb-Girdle Muscular Dystrophy Markers
MT Newswires · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.